Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.
Not all older adults can get monoclonal antibodies for Alzheimer’s disease, study finds
By
Kristen Fischer
Sep 22, 2023
Even though newer monoclonal antibodies are available for Alzheimer’s disease, there are limits on the number of older adults who can receive them, a recent study published in Neurology finds.
FDA approves new drug Leqembi to treat early Alzheimer’s disease
By
Alicia Lasek
Jan 09, 2023
The newly approved drug Leqembi (lecanemab) may slow progression of cognitive decline due to Alzheimer’s disease, trial data show. CMS says it may rethink Medicare coverage of drugs in Leqembi’s...
Race, ethnicity help determine which controllable risk factors for dementia have biggest impacts
By
Kristen Fischer
Jan 18, 2024
Controllable risk factors that factor into Alzheimer’s or dementia cases play varying roles based on someone’s race and ethnicity, a new study shows.